Primary Sclerosing Cholangitis (PSC) Market

1. Primary Sclerosing Cholangitis (PSC) Market Primary Sclerosing Cholangitis (PSC) is a condition that affects the bile ducts. It occurs because of inflammation in the bile ducts (cholangitis) that leads to scarring (sclerosis) and narrowing of the ducts. As a result, bile cannot be released to the gallbladder and small intestine, and it builds up in the liver. DelveInsight's "Primary Sclerosing Cholangitis (PSC) - Market Insights, Epidemiology, and Market Forecast- 2030" report delivers an in-depth understanding of the Primary Sclerosing Cholangitis (PSC), historical and forecasted epidemiology as well as the Primary Sclerosing Cholangitis (PSC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Primary Sclerosing Cholangitis (PSC) market report provides current treatment practices, emerging drugs, Primary Sclerosing Cholangitis (PSC) market share of the individual therapies, current and forecasted Primary Sclerosing Cholangitis (PSC) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Primary Sclerosing Cholangitis (PSC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. Geography Covered    The United States EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan Study Period:2017-2030 Download sample pages: https://www.delveinsight.com/sample- request/primary-sclerosing-cholangitis-market Primary Sclerosing Cholangitis (PSC) Disease Understanding and Treatment Algorithm Primary Sclerosing Cholangitis is thought to arise from a combination of genetic and environmental factors. Researchers believe that genetic changes play a role in this condition because it often occurs in several members of a

2. family and because immediate family members of someone with primary sclerosing cholangitis have an increased risk of developing the condition. The symptoms associated with PSC include fatigue and itching (pruritus), followed by yellowing of the skin, mucous membranes, and whites of the eyes (jaundice). Other symptoms may include losing weight without trying, poor appetite, fever, and pain in the abdomen. The DelveInsight Primary Sclerosing Cholangitis (PSC) market report gives a thorough understanding of the Primary Sclerosing Cholangitis (PSC) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. Diagnosis This segment of the report covers the detailed diagnostic methods or tests for Primary Sclerosing Cholangitis (PSC). Treatment It covers the details of conventional and current medical therapies available in the Primary Sclerosing Cholangitis (PSC) market for the treatment of the condition. It also provides Primary Sclerosing Cholangitis (PSC) treatment algorithms and guidelines in the United States, Europe, and Japan. Request for sample pages: https://www.delveinsight.com/sample- request/primary-sclerosing-cholangitis-market Primary Sclerosing Cholangitis (PSC) Epidemiology The Primary Sclerosing Cholangitis (PSC) epidemiology division provide insights about historical and current Primary Sclerosing Cholangitis (PSC)patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. Key facts: • Primary sclerosing cholangitis is a rare disorder that affects males twice as often as females. Although it may affect individuals of any age, the disorder most often occurs in middle-aged adults. • The exact incidence and prevalence of the disorder is unknown. One estimate places the incidence at approximately 1 person per each 100,000 in the general population in the United States or Europe. Primary Sclerosing Cholangitis (PSC) Drug Chapters In the coming years, the competitive landscape for the Primary Sclerosing Cholangitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. Major players, such as Gilead Sciences, HighTide Therapeutics, Tobira Therapeutics and NGM Biopharmaceuticals are involved in developing therapies for Primary Sclerosing Cholangitis. Launch of emerging therapies, such as GS-9674 (Gilead Sciences), HTD1801 (HighTide Therapeutics), Cenicriviroc (Tobira Therapeutics) and NGM282 (NGM Biopharmaceuticals) will significantly impact the Primary Sclerosing Cholangitis market during the study period (2017–2030). Drug chapter segment of the Primary Sclerosing Cholangitis (PSC) report encloses the detailed analysis of Primary Sclerosing Cholangitis (PSC) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Primary Sclerosing Cholangitis (PSC)clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

3. Marketed Drugs The report provides the details of the marketed product available for Primary Sclerosing Cholangitis (PSC) treatment. Primary Sclerosing Cholangitis (PSC) Emerging Drugs The report provides the details of the emerging therapies under the late and mid-stage of development for Primary Sclerosing Cholangitis (PSC) treatment. Primary Sclerosing Cholangitis (PSC) Market Outlook The treatment of PSC focuses on managing the complications and monitoring the liver damage. There have been several medications which are studied in people with Primary Sclerosing Cholangitis, but so far none have been found to slow or reverse the liver damage associated with this disease. The pharmacotherapy is aimed at treating symptoms and managing complications. Immuno-suppressants, bile salts, chelators (eg, cholestyramine for pruritus), and steroids are used in an attempt to control the disease process but have not shown significant benefit. The further treatment depends on the stage and degree of progression of the disease. There are two major treatment goals in PSC: slow or reverse disease progression and management of symptoms of disease progression. The Primary Sclerosing Cholangitis (PSC) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Primary Sclerosing Cholangitis (PSC)markettrends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. According to DelveInsight, Primary Sclerosing Cholangitis (PSC)market in 7MM is expected to change in the study period 2017-2030. Click here and get access to our full report. Click here and request to download our sample pages.